Live
- From Self-Doubt to Self-Love: Vange Cain’s Inspirational Path
- Rahul Gandhi remembers Balasaheb Thackeray on his death anniversary
- Tomato prices drop 22.5 pc as flow of fresh crop picks up pace
- Heavy police deployment in TN's Madurai after protest against airport expansion
- Meghalaya: NEHU students’ protest enters day 13; civil society body intervenes
- Lambada Samithi slams govt for atrocities on tribals
- Manoj Tiwari criticises AAP, promises 'double-engine govt' in Delhi
- Nigeria to honour PM Modi with second-highest national award GCON
- Apex Meitei body gives 24-hrs to Manipur, Central govts to take 'decisive action', residences of Ministers, MLAs attacked
- MLA hails environ-friendly ventures by entrepreneurs
Scientist a human guinea pig for malaria vaccine
In a world first a new malaria vaccine developed by Australian scientists has passed its first test in early human trials. Queensland scientists will ramp up tests of the vaccine, after its inventor tried it out by giving himself the disease.
​Canberra: In a world first a new malaria vaccine developed by Australian scientists has passed its first test in early human trials. Queensland scientists will ramp up tests of the vaccine, after its inventor tried it out by giving himself the disease.
The vaccine, called PlasProtecT, developed by the researchers at Griffith University consists of inactivated human malaria parasites which have been prevented from growing and causing a malaria infection.
The vaccine works by stimulating a natural immune response which can protect a person for years against the mosquito-borne disease.
Lead researcher Michael Good, an immunologist with Griffith's Institute for Glycomics, was the first person to be immunised.
"I wouldn't ask people to do what I wouldn't be prepared to do, and we couldn't do this without the volunteers who give their time to us knowing they are helping further work towards a cure," Prof Good said.
It was later tested on another 11 people and proven to be safe and effective. "This is a world first," Gold Coast Health Director of Infectious Diseases Dr John Gerrard said.
"We are the first to put a vaccine like this into humans that has potential to protect against multiple strains and species of malaria," he said.
A much larger human clinical trial is now planned that will involve injecting participants with three doses of the vaccine and then infecting them with malaria to test the protection the vaccination provides.
Malaria is a mosquito-borne disease that kills up to half a million people each year, the vast majority of them children.
PlasProtecT represents a huge step forward in the fight against malaria, says Associate Professor Richard Culleton from the Malaria Unit at the Institute of Tropical Medicine at Nagasaki University in Japan.
Most excitingly, he says, the trials have shown that this human immune response also recognises other strains and even other species of the parasite.
"There are many different strains and species of malaria parasite in circulation, and finding a vaccine that can protect against them all has proven particularly troublesome so far," Prof Good said.
